Hansa Financial Statements From 2010 to 2024
| HNSA Stock | SEK 31.00 0.50 1.59% |
Check Hansa Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hansa Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Hansa financial statements analysis is a perfect complement when working with Hansa Biopharma Valuation or Volatility modules.
Hansa |
Hansa Biopharma AB Company Operating Margin Analysis
Hansa Biopharma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Hansa Biopharma Operating Margin | (3.80) % |
Most of Hansa Biopharma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Hansa Biopharma AB has an Operating Margin of -3.7991%. This is 89.17% lower than that of the Healthcare sector and 96.61% lower than that of the Biotechnology industry. The operating margin for all Sweden stocks is 31.05% lower than that of the firm.
Hansa Biopharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hansa Biopharma's current stock value. Our valuation model uses many indicators to compare Hansa Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hansa Biopharma competition to find correlations between indicators driving Hansa Biopharma's intrinsic value. More Info.Hansa Biopharma AB is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hansa Biopharma's earnings, one of the primary drivers of an investment's value.About Hansa Biopharma Financial Statements
Hansa Biopharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Hansa Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Hansa Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Hansa Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.